Ronald McClurg - Neuroone Medical Chief Officer
| NMTC Stock | USD 0.76 0.02 2.70% |
Insider
Ronald McClurg is Chief Officer of Neuroone Medical Technologies
| Age | 64 |
| Address | 7599 Anagram Drive, Eden Prairie, MN, United States, 55344 |
| Phone | 952 426 1383 |
| Web | https://www.n1mtc.com |
Ronald McClurg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald McClurg against Neuroone Medical stock is an integral part of due diligence when investing in Neuroone Medical. Ronald McClurg insider activity provides valuable insight into whether Neuroone Medical is net buyers or sellers over its current business cycle. Note, Neuroone Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neuroone Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald McClurg over a year ago Purchase by Ronald McClurg of 50900 shares of Neuroone Medical |
Neuroone Medical Management Efficiency
The company has return on total asset (ROA) of (1.4333) % which means that it has lost $1.4333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4913) %, meaning that it created substantial loss on money invested by shareholders. Neuroone Medical's management efficiency ratios could be used to measure how well Neuroone Medical manages its routine affairs as well as how well it operates its assets and liabilities. At present, Neuroone Medical's Return On Equity is projected to drop based on the last few years of reporting. At present, Neuroone Medical's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 377 K, whereas Total Assets are forecasted to decline to about 3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lucy Liu | Biomerica | N/A | |
| Budimir Drakulic | BioSig Technologies, Common | 74 | |
| Peter Stegagno | SANUWAVE Health | 63 | |
| Christopher Jones | Nortech Systems Incorporated | 53 | |
| MS MBA | Delcath Systems | 61 | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Steven CPA | BioSig Technologies, Common | 70 | |
| John Sieckhaus | BioSig Technologies, Common | 56 | |
| Michael Leabman | Movano Inc | 51 | |
| John MS | Delcath Systems | 63 | |
| Brenda Castrodad | BioSig Technologies, Common | N/A | |
| Kevin II | SANUWAVE Health | 55 | |
| Iulian Cioanta | SANUWAVE Health | 60 | |
| Mark Saxton | Neuropace | 59 | |
| Richard Ginn | Tenon Medical | 58 | |
| Alan Connaughton | LENSAR Inc | 52 | |
| Anthony Dias | Delcath Systems | 57 | |
| Rebecca Kuhn | Neuropace | 63 | |
| Robert Carlson | Biomerica | N/A | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| Jack Schlechtweg | SANUWAVE Health | 43 | |
Management Performance
| Return On Equity | -3.49 | ||||
| Return On Asset | -1.43 |
Neuroone Medical Tec Leadership Team
Elected by the shareholders, the Neuroone Medical's board of directors comprises two types of representatives: Neuroone Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuroone. The board's role is to monitor Neuroone Medical's management team and ensure that shareholders' interests are well served. Neuroone Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuroone Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher CFA, Chief Officer | ||
| Hijaz Haris, Vice Marketing | ||
| Ronald McClurg, Chief Officer | ||
| Mark Christianson, Business CoFounder | ||
| David MD, CEO President | ||
| Steven Mertens, Chief Officer |
Neuroone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neuroone Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.49 | ||||
| Return On Asset | -1.43 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 22.18 M | ||||
| Shares Outstanding | 30.84 M | ||||
| Shares Owned By Insiders | 16.01 % | ||||
| Shares Owned By Institutions | 19.43 % | ||||
| Number Of Shares Shorted | 95.52 K | ||||
| Price To Earning | (23.53) X | ||||
| Price To Book | 28.45 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.